R-Pharm International, LLC clinical trials

A subsidiary of R-Pharm

The registry lists 17 studies whose lead sponsor is R-Pharm International, LLC. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 30, 2026.

Studies

Recruiting first, then most recently updated. Showing 17 of 17. All R-Pharm studies →

• Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's DiseaseNot yet recruitingNCT07625384Phase 3

  Sponsor listed in the registry: R-Pharm International, LLC

• Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic ArthritisRecruitingNCT07517575Phase 2

  Sponsor listed in the registry: R-Pharm International, LLC

• Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean FeverRecruitingNCT05190991Phase 2

  Sponsor listed in the registry: R-Pharm International, LLC

• Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung DiseasesRecruitingNCT06440746Phase 2/3

  Sponsor listed in the registry: R-Pharm International, LLC

• Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)Active, not recruitingNCT07670546Phase 3

  Sponsor listed in the registry: R-Pharm International, LLC

• A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT07553988Phase 2

  Sponsor listed in the registry: R-Pharm International, LLC

• Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy VolunteersCompletedNCT07206043Phase 1

  Sponsor listed in the registry: R-Pharm International, LLC

• Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of ColchicineActive, not recruitingNCT05092776Phase 2

  Sponsor listed in the registry: R-Pharm International, LLC

• Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)WithdrawnNCT05432960Phase 3

  Sponsor listed in the registry: R-Pharm International, LLC

• Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent PericarditisActive, not recruitingNCT05673902Phase 3

  Sponsor listed in the registry: R-Pharm International, LLC

• Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4CompletedNCT04246762Phase 1

  Sponsor listed in the registry: R-Pharm International, LLC

• Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisCompletedNCT03120949Phase 3

  Sponsor listed in the registry: R-Pharm International, LLC

• Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseCompletedNCT02760368Phase 3

  Sponsor listed in the registry: R-Pharm International, LLC

• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseCompletedNCT02760407Phase 3

  Sponsor listed in the registry: R-Pharm International, LLC

• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active DiseaseCompletedNCT02760433Phase 3

  Sponsor listed in the registry: R-Pharm International, LLC

• Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent PericarditisCompletedNCT04692766Phase 2/3

  Sponsor listed in the registry: R-Pharm International, LLC

• Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)CompletedNCT04380519Phase 2/3

  Sponsor listed in the registry: R-Pharm International, LLC